Raymond W. Hasse CRC

IMG_6787.jpeg

Page updated: September 3, 2024

(This page is reachable via rwhcrc.com and at tiny.cc/rwhcrc )

โปรดคลิกลิงก์ด้านล่างเพื่อดูข้อมูลผู้ป่วยที่ครอบคลุมสามารถดาวน์โหลดได้ ซึ่งรวมถึงผลการตรวจเลือดและผลเอกซ์เรย์ หากคุณต้องการข้อมูลเพิ่มเติม โปรดดูข้อมูลการติดต่อด้านล่าง

(This page scrolls, and some data charts scroll. If you would like other data please let us know)

PT: Raymond W. Hasse, Retired US Navy scientist; DOB: August 7, 1924

Bangkok Hospital Pattaya HN 02-19-010632

Bangkok Hospital Bangkok HN 01-21-062259

Bumrungrad, Bangkok HN 800-30-1226

UCSF, San Francisco MRN: 61856633

Contact info (link)

Brief

Raymond's CEA has shown elevate levels since February of 2024: from 10.0 to 14.50. Raymond had a "positive result" ("abnormal") from a ctDNA test (GuardantShield) in early May 2024, which indicates that further investigation is due. Guardant’s Shield blood test was approved by the US FDA as a primary screening for CRC in July of 2024.

Patient had an FDG-PET-CT on June 12, 2024. Apparently it did not show signs of cancer, per that radiologist’s reading.

An SDC-2 methylation stool test (July 2024) had negative results.

<aside> 💡 The current questions are whether to proceed with a colonoscopy and or endoscopy, as well as if other investigations are appropriate (e.g. capsule endoscopy, etc.)

</aside>

Upon discovery of a stage 1-3 colorectal cancer (CRC), it appears that the best route would be to start immunotherapy, in particular dostarlimab, if available. Perhaps there is some other cancer present that for some reason is causing the GuardantShield test to show “positive.” Perhaps some other testing or investigation is warranted.